Expression of Gadd45a and p53 proteins in human pancreatic cancer: Potential effects on clinical outcomes

Journal of Surgical Oncology

Volumn 95, Issue 4, 2007, Pages 332-336

  Dong, Ming ^a   Dong, Qi ^b   Zhang, Hao ^a   Zhou, Jianping ^a   Tian, Yulin ^a   Dong, Yuting ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b People s Hospital of Liaoning Province   (China)

Author keywords

Gadd45a; Immunohistochemistry; p53; Pancreatic cancer

Indexed keywords

GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR DIFFERENTIATION;

ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; CELL CYCLE PROTEINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33847690651     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20684     Document Type: Article

References (13)

1. Dong M, Dong YT: Present status of study on risk factors of pancreatic carcinogenesis. Chin J Gen Surg 2003;18:405-406. (in Chinese)
2. Jin S, Mazzacurati L, Zhu X, et al.: Gadd45a contributes to p53 stabilization in response to DNA damage. Oncogene 2003;22: 8536-8540.
3. Nio Y, Dong M, Uegaki K, et al.: p53 expression affects the efficacy of adjuvant chemotherapy after resection of invasive ductal carcinoma of the pancreas. Anticancer Res 1998;18:3773-3779.
4. Yamasawa K, Nio Y, Dong M, et al.: Clinicopathological significances in Gadd45 expression and its relationship to p53 in human pancreatic cancer. Clin Cancer Res 2002;8:2563-2569.
5. Melhem MF, Law JC, el-Ashmawy L, et al.: Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am J Pathol 1995;146:1170-1177.
6. Sobin LH, Wittekind Ch: TNM Classification of Malignant Tumours, 5th edition. New York: John Wiley and Sons, Inc.; 1997. pp 87-90.
7. Dong M, Nio Y, Tamura K, et al.: Ki-ras point mutation and p53 expression in human pancreatic cancer: A comparative study among Chinese, Japanese, and Western patients. Cancer Epidemiol Biomarkers Prev 2000;9:279-284.
8. Sato Y, Nio Y, Song MM, et al.: p53 protein expression as prognostic factor in human pancreatic cancer. Anticancer Res 1997;17:2779-2788.
9. Nakamori S, Yashima K, Murakami Y, et al.: Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jpn J Cancer Res 1995;86:174-181.
10. 2 protein expression in human pancreatic cancer. World J Gastroenterol 2005;11:2162-2165.
11. Hollander MC, Kovalsky O, Salvador JM, et al.: Dimethylbenzanthracene carcinogenesis in Gadd45a-null mice is associated with decreased DNA repair and increased mutation frequency. Cancer Res 2001;61:2487-2491.
12. Hildesheim J, Belova GI, Tyner SD, et al.: Gadd45a regulates matrix metalloproteinases by suppressing Delta Np63 alpha and beta-catenin via p38 MAP kinase and APC complex activation. Oncogene 2004;23:1829-1837.
13. 2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci USA 1994;91:2684-2688.